Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CYT-100
- Development stage
- Unknown
- Lead developer
- Cytovia
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CYT-100 is an allogeneic, induced pluripotent stem cell (iPSC)-derived natural killer (NK) cell therapy developed by Cytovia Therapeutics. It is designed as an "off-the-shelf" treatment for solid tumors, with a primary focus on hepatocellular carcinoma (HCC). By utilizing a standardized iPSC master cell bank, CYT-100 aims to provide a consistent and scalable alternative to patient-derived or donor-derived NK cell therapies. The therapy leverages the innate anti-tumor activity of NK cells, which can recognize and kill cancer cells without prior sensitization. Cytovia has integrated TALEN gene-editing technology into its platform to enhance the persistence and efficacy of its iNK cells, although CYT-100 serves as the foundational, non-CAR-engineered version of the therapy.
- Other names
- iNK cell therapyiPSC-derived NK cells
Beyond the preview
Go deeper on CYT-100.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CYT-100.